Issue 19, 2016

Co-delivery of paclitaxel and indocyanine green by PEGylated graphene oxide: a potential integrated nanoplatform for tumor theranostics

Abstract

Herein, we have prepared PEGylated nano graphene oxide (NGO-PEG) that co-delivers paclitaxel (PTX) and indocyanine green (ICG) for tumor theranostics, integrating fluorescence imaging and chemotherapy. First, polyethylene glycol (PEG) with a dual-terminal amine was covalently conjugated with NGO to obtain the NGO-PEG. Furthermore, ICG, a near-infrared (NIR) Food and Drug Administration (FDA) approved fluorescent dye was covalently loaded onto NGO-PEG as a fluorescence contrast agent, NGO-PEG–ICG. PTX, a widely clinical used anti-cancer drug, was non-covalently immobilized onto the NGO surface via π–π stacking interaction and hydrogen bonding, giving the multifunctional nano-composite, NGO-PEG–ICG/PTX. The obtained nano-composite had great stability and biocompatibility. NGO-PEG showed (50 ± 2.1)% and (90 ± 1.6)% (w/w) of ICG and PTX loading ratios, respectively, which were determined from a UV-visible spectrometer. The fluorescence signal endowed by ICG was detected in the cytoplasm using confocal microscopy, demonstrating the high-efficiency human osteosarcoma (MG-63) cell uptake of NGO-PEG–ICG/PTX. Moreover, NGO-PEG–ICG/PTX could cause decreased cell viability compared to the same concentration of free PTX, revealing the excellent chemotherapeutic effect of NGO-PEG–ICG/PTX in vitro. In vivo fluorescence imaging results indicated a high MG-63 tumor accumulation of NGO-PEG–ICG/PTX, which could reach the maximum content in tumors at about 29.1% dose per g tissue at 24 h post injection with about eight days of tumor retention. Based on these encouraging results, the NGO-PEG–ICG/PTX was tail vein injected into tumor-bearing mice at day one and day eight, and the tumor-bearing mice showed complete tumor suppression or no relapse and treatment-induced major organ lesions over one-month of treatment. These results suggested that the synthesized versatile NGO-PEG–ICG/PTX with a high fluorescence contrast and chemotherapeutic effect can be a potential tumor theranostic nanoplatform.

Graphical abstract: Co-delivery of paclitaxel and indocyanine green by PEGylated graphene oxide: a potential integrated nanoplatform for tumor theranostics

Supplementary files

Article information

Article type
Paper
Submitted
01 Dec 2015
Accepted
10 Jan 2016
First published
14 Jan 2016

RSC Adv., 2016,6, 15460-15468

Author version available

Co-delivery of paclitaxel and indocyanine green by PEGylated graphene oxide: a potential integrated nanoplatform for tumor theranostics

C. Zhang, T. Lu, J. Tao, G. Wan and H. Zhao, RSC Adv., 2016, 6, 15460 DOI: 10.1039/C5RA25518J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements